Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OSU 6162

Next Previous
Drug Profile

OSU 6162

Alternative Names: Movement disorder therapeutics - Pfizer; OSU6162; PNU-9639; PNU-96391; PNU-96391A

Latest Information Update: 20 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Carlsson Research AB
  • Developer Carlsson Research AB; Goteborg University; NeuroSearch; Oslo University Hospital; Pfizer
  • Class Antidepressants; Antipsychotics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bipolar depression; Chronic fatigue syndrome; Depressive disorders; Stroke; Subarachnoid haemorrhage
  • Discontinued Parkinson's disease

Most Recent Events

  • 21 Apr 2022 Phase-II clinical trials in Depressive disorders (Treatment-resistant, In adults, In the elderly, Adjunctive treatment) in Sweden (PO) (NCT05641623)
  • 25 Oct 2021 Phase-II clinical trials in Bipolar depression in Sweden (PO) (NCT05296356)
  • 23 Mar 2021 Carlsson Research AB completes a phase I/II trial in Chronic fatigue syndrome in Sweden (PO, Capsule) (EudraCT2011-001650-29)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top